➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Moodys
Harvard Business School
Colorcon
Baxter

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Patent: 7,507,704

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,507,704
Title:Receptor modulated cancer protocols
Abstract: The present invention discloses that prior art protocols that administer HER receptor blockers concurrently with phase specific cytotoxic chemotherapeutics result in antagonistic function that prevents subsequent administrations of phase specific cytotoxic from functioning. The present invention provides protocols that allow the two classes of drugs to function synergistically. Moreover, the present invention also identifies that gompertzian tumor growth results in heterogeneity of cell cycle times in a tumor and that chemotherapeutic depopulation of the tumor results in accelerating cell cycle times, both of which preclude synchronicity of successive administrations of S-Phase cytotoxics relative to the progression of the S-Phase in the cancer cell population under prior art protocols. Present invention provides novel \"synchronous\" protocols for S-Phase cytotoxics, using HER blockers, to overcome this problem. Present invention also discloses how to integrate protocols of U.S. Pat. No. 6,486,146 for HER+ cancers that are also endocrine dependent.
Inventor(s): Zamoyski; Mark (San Jose, CA)
Assignee:
Application Number:11/809,264
Patent Claims:see list of patent claims

Details for Patent 7,507,704

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial 2022-11-15 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial 2022-11-15 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial 2022-11-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Colorcon
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.